Journal: Scientific Reports

Article Title: Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma

doi: 10.1038/s41598-025-14572-1

Figure Lengend Snippet: The cytotoxic activity of c-SF-25-PBL-sup on KUT-1 cells. ( a ) Effect of the c-SF-25-PBL-sup on the proliferation of KUT-1 cells . Neutralization of anti-FasL Mab, anti-IFN-γ, TNF-α or the combinations of anti-FasL Mab, anti- IFN-γ, and TNF-α did not neutralize the cytotoxic activity of the c-SF-25-PBL-sup to KUT-1 cells. ( b , c ) The morphological changes in KUT-1 cells cultured in the presence of c-SF-25-PBL-sup derived from healthy participants. ( d ) DNA fragmentation was observed in the KUT-1 cells treated with mu-SF-25-PBL-sup. FasL Fas ligand; IFN-γ interferon–γ; TNF-α tumor necrosis factor-α.

Article Snippet: The MTT assay was also performed in the presence of neutralizing anti-human TNF-α rabbit polyclonal antibody (Genzyme, Cambridge, MA., U.S.A.), anti-human IFN-γ polyclonal antibody (PeproTech, Rocky Hill, N.J., U.S.A.), or anti-FasL Mab (clone 4H9; MBL) to assess the roles of TNF-α, IFN-γ, and sFasL in the c-SF-25-PBL-sup.

Techniques: Activity Assay, Neutralization, Cell Culture, Derivative Assay